- Home
- CR vs ROIV Comparison
CR vs ROIV Comparison
Compare CR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | ROIV |
|---|---|---|
| Founded | 1855 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 20.7B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CR | ROIV |
|---|---|---|
| Price | $172.75 | $28.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $223.40 | $27.56 |
| AVG Volume (30 Days) | 343.8K | ★ 4.8M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | ★ 23.96 | N/A |
| EPS | ★ 6.26 | N/A |
| Revenue | ★ $2,305,000,000.00 | $29,053,000.00 |
| Revenue This Year | $28.11 | N/A |
| Revenue Next Year | $5.76 | $385.85 |
| P/E Ratio | $28.68 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $127.04 | $8.73 |
| 52 Week High | $214.31 | $30.33 |
Technical Indicators
Market Signals| Indicator | CR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 29.07 | 53.51 |
| Support Level | N/A | $26.94 |
| Resistance Level | $191.15 | N/A |
| Average True Range (ATR) | 6.32 | 1.01 |
| MACD | -3.04 | -0.21 |
| Stochastic Oscillator | 0.00 | 32.70 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.